{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T05:04:43Z","timestamp":1773983083091,"version":"3.50.1"},"reference-count":49,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.vaccine.2021.01.061","type":"journal-article","created":{"date-parts":[[2021,2,5]],"date-time":"2021-02-05T02:26:56Z","timestamp":1612492016000},"page":"1370-1382","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Modelling a cost-effective vaccination strategy for the prevention of varicella and herpes zoster infection: A systematic review"],"prefix":"10.1016","volume":"39","author":[{"given":"Brent","family":"Hodgkinson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3957-0209","authenticated-orcid":false,"given":"Tianjiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua","family":"Byrnes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5931-642X","authenticated-orcid":false,"given":"Paul","family":"Scuffham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2021.01.061_b0005","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/S0140-6736(06)69561-5","article-title":"Varicella","volume":"368","author":"Heininger","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2021.01.061_b0010","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/1471-2334-13-170","article-title":"Similar herpes zoster incidence across Europe: results from a systematic literature review","volume":"13","author":"Pinchinat","year":"2013","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2021.01.061_b0015","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s40259-016-0180-7","article-title":"Shingles (Herpes Zoster) Vaccine (Zostavax(\u00a0)): A Review in the Prevention of Herpes Zoster and Postherpetic Neuralgia","volume":"30","author":"Keating","year":"2016","journal-title":"Biodrugs"},{"key":"10.1016\/j.vaccine.2021.01.061_b0020","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1128\/CMR.9.3.361","article-title":"Varicella-zoster virus","volume":"9","author":"Arvin","year":"1996","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.vaccine.2021.01.061_b0025","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/j.jstrokecerebrovasdis.2016.03.052","article-title":"Varicella Zoster Virus: A Common Cause of Stroke in Children and Adults","volume":"25","author":"Amlie-Lefond","year":"2016","journal-title":"J Stroke Cerebrovascular Dis"},{"key":"10.1016\/j.vaccine.2021.01.061_b0030","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/j.vaccine.2014.10.071","article-title":"Febrile seizures following measles and varicella vaccines in young children in Australia","volume":"33","author":"Macartney","year":"2015","journal-title":"Vaccine."},{"key":"10.1016\/j.vaccine.2021.01.061_b0035","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1086\/315714","article-title":"Varicella mortality: trends before vaccine licensure in the United States, 1970\u20131994","volume":"182","author":"Meyer","year":"2000","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2021.01.061_b0040","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.vaccine.2008.11.012","article-title":"Herpes zoster burden of illness and health care resource utilisation in the Australian population aged 50 years and older","volume":"27","author":"Stein","year":"2009","journal-title":"Vaccine."},{"key":"10.1016\/j.vaccine.2021.01.061_b0045","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.cger.2007.03.003","article-title":"Herpes zoster and postherpetic neuralgia in older adults","volume":"23","author":"Schmader","year":"2007","journal-title":"Clin Geriatr Med"},{"key":"10.1016\/j.vaccine.2021.01.061_b0050","doi-asserted-by":"crossref","first-page":"S130","DOI":"10.1016\/j.jaad.2007.08.046","article-title":"Herpes zoster: epidemiology, natural history, and common complications","volume":"57","author":"Weinberg","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.vaccine.2021.01.061_b0055","doi-asserted-by":"crossref","unstructured":"McIntyre P, Gidding H, Gilmour R, Lawrence G, Hull B, Horby P. Vaccine preventable diseases and vaccination coverage in Australia, 1999\u20132000. Communicable Diseases Intelligence 2002;24 1-111.","DOI":"10.33321\/cdi.2002.26.12"},{"key":"10.1016\/j.vaccine.2021.01.061_b0060","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1046\/j.1440-1754.1998.00146.x","article-title":"Direct and indirect costs of chickenpox in young children","volume":"34","author":"Ferson","year":"1998","journal-title":"J Paediatr Child Health"},{"key":"10.1016\/j.vaccine.2021.01.061_b0065","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jinf.2016.05.008","article-title":"The burden of hospitalisation for varicella and herpes zoster in England from 2004 to 2013","volume":"73","author":"Hobbelen","year":"2016","journal-title":"J Infect"},{"key":"10.1016\/j.vaccine.2021.01.061_b0070","doi-asserted-by":"crossref","first-page":"238","DOI":"10.4161\/hv.4.3.5686","article-title":"The potential cost-effectiveness of vaccination against herpes zoster and post-herpetic neuralgia","volume":"4","author":"Brisson","year":"2008","journal-title":"Human Vaccines"},{"key":"10.1016\/j.vaccine.2021.01.061_b0075","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s10198-003-0200-7","article-title":"The burden of varicella in Germany. Potential risks and economic impact","volume":"5","author":"Banz","year":"2004","journal-title":"European J Health Economics"},{"key":"10.1016\/j.vaccine.2021.01.061_b0080","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/s12879-015-0951-7","article-title":"Burden of herpes zoster and post-herpetic neuralgia in Sweden","volume":"15","author":"Nilsson","year":"2015","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2021.01.061_b0085","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1007\/s10198-012-0452-1","article-title":"Epidemiology and cost of herpes zoster and postherpetic neuralgia in Germany","volume":"14","author":"Ultsch","year":"2013","journal-title":"European J Health Economics"},{"key":"10.1016\/j.vaccine.2021.01.061_b0090","doi-asserted-by":"crossref","first-page":"4167","DOI":"10.1016\/S0264-410X(03)00534-6","article-title":"The cost of measles in industrialised countries","volume":"21","author":"Carabin","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.01.061_b0095","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1542\/peds.2004-0012","article-title":"Decline in varicella-related hospitalizations and expenditures for children and adults after introduction of varicella vaccine in the United States","volume":"114","author":"Davis","year":"2004","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2021.01.061_b0100","doi-asserted-by":"crossref","first-page":"593","DOI":"10.2471\/BLT.13.132142","article-title":"Varicella and herpes zoster hospitalizations before and after implementation of one-dose varicella vaccination in Australia: an ecological study","volume":"92","author":"Heywood","year":"2014","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.vaccine.2021.01.061_b0105","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2165\/10489140-000000000-00000","article-title":"Zoster vaccine (Zostavax): a review of its use in preventing herpes zoster and postherpetic neuralgia in older adults","volume":"27","author":"Sanford","year":"2010","journal-title":"Drugs Aging"},{"key":"10.1016\/j.vaccine.2021.01.061_b0110","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/cid\/cis638","article-title":"Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy","volume":"55","author":"Schmader","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2021.01.061_b0115","doi-asserted-by":"crossref","first-page":"6980","DOI":"10.1016\/j.vaccine.2006.04.051","article-title":"Economic evaluation of varicella vaccination in Spain: results from a dynamic model (Structured abstract)","volume":"24","author":"Lenne","year":"2006","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2021.01.061_b0120","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.clinthera.2015.01.006","article-title":"Cost-effectiveness of routine varicella vaccination using the measles, mumps, rubella and varicella vaccine in France: an economic analysis based on a dynamic transmission model for varicella and herpes zoster","volume":"37","author":"Littlewood","year":"2015","journal-title":"Clin Ther"},{"key":"10.1016\/j.vaccine.2021.01.061_b0125","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S0277-9536(99)00115-X","article-title":"The cost-effectiveness of introducing a varicella vaccine to the New Zealand immunisation schedule","volume":"49","author":"Scuffham","year":"1999","journal-title":"Soc Sci Med"},{"key":"10.1016\/j.vaccine.2021.01.061_b0130","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0264-410X(99)00261-3","article-title":"The cost-effectiveness of varicella vaccine programs for Australia (Structured abstract)","volume":"18","author":"Scuffham","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.01.061_b0135","doi-asserted-by":"crossref","first-page":"6281","DOI":"10.1016\/j.vaccine.2008.07.021","article-title":"Cost-effectiveness analysis of universal childhood vaccination against varicella in Brazil (Structured abstract)","volume":"26","author":"Valentim","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.01.061_b0140","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1016\/S0264-410X(01)00044-5","article-title":"The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales","volume":"19","author":"Edmunds","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.01.061_b0145","doi-asserted-by":"crossref","first-page":"8326","DOI":"10.1016\/j.vaccine.2007.09.066","article-title":"Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults","volume":"25","author":"Pellissier","year":"2007","journal-title":"Vaccine."},{"key":"10.1016\/j.vaccine.2021.01.061_b0150","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1177\/003591576505800106","article-title":"The Nature of Herpes Zoster: A Long-Term Study and a New Hypothesis","volume":"58","author":"Hope-Simpson","year":"1965","journal-title":"Proc Royal Soc Med"},{"key":"10.1016\/j.vaccine.2021.01.061_b0155","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1017\/S0950268800004714","article-title":"Modelling the impact of immunization on the epidemiology of varicella zoster virus","volume":"125","author":"Brisson","year":"2000","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.vaccine.2021.01.061_b0160","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jval.2013.02.002","article-title":"Consolidated Health Economic Evaluation Reporting Standards (CHEERS)\u2014Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force","volume":"16","author":"Husereau","year":"2013","journal-title":"Value Health"},{"key":"10.1016\/j.vaccine.2021.01.061_b0165","unstructured":"The Campbell and Cochrane Economics Methods Group (CCEMG). CCEMG - EPPI-Centre Cost Converter v1.6. 2019."},{"key":"10.1016\/j.vaccine.2021.01.061_b0170","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1136\/adc.88.10.862","article-title":"Varicella vaccination in England and Wales: cost-utility analysis","volume":"88","author":"Brisson","year":"2003","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.vaccine.2021.01.061_b0175","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0220921","article-title":"Cost-effectiveness analysis of universal varicella vaccination in Turkey using a dynamic transmission model","volume":"14","author":"Wolfson","year":"2019","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2021.01.061_b0180","doi-asserted-by":"crossref","first-page":"812","DOI":"10.4161\/hv.23334","article-title":"Childhood varicella-zoster virus vaccination in Belgium: cost-effective only in the long run or without exogenous boosting? (Provisional abstract)","author":"Bilcke","year":"2013","journal-title":"Human Vaccines Immunotherapeut"},{"key":"10.1016\/j.vaccine.2021.01.061_b0185","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-018-1094-7","article-title":"The impact of demographic changes, exogenous boosting and new vaccination policies on varicella and herpes zoster in Italy: A modelling and cost-effectiveness study","volume":"16","author":"Melegaro","year":"2018","journal-title":"BMC Med"},{"key":"10.1016\/j.vaccine.2021.01.061_b0190","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/j.vaccine.2011.11.026","article-title":"The cost-effectiveness of varicella and combined varicella and herpes zoster vaccination programmes in the United Kingdom (Structured abstract)","volume":"30","author":"van Hoek","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.01.061_b0195","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1177\/0272989X12454578","article-title":"Dynamic Transmission Modeling: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group\u20135","volume":"32","author":"Pitman","year":"2012","journal-title":"Med Decis Making"},{"key":"10.1016\/j.vaccine.2021.01.061_b0200","doi-asserted-by":"crossref","first-page":"e60732","DOI":"10.1371\/journal.pone.0060732","article-title":"Perspectives on the impact of varicella immunization on herpes zoster. A model-based evaluation from three European countries","volume":"8","author":"Poletti","year":"2013","journal-title":"PLoS ONE [Electronic Resource]."},{"key":"10.1016\/j.vaccine.2021.01.061_b0205","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/S0264-410X(01)00437-6","article-title":"The cost-effectiveness of varicella vaccination in Canada (Structured abstract)","volume":"20","author":"Brisson","year":"2002","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2021.01.061_b0210","doi-asserted-by":"crossref","first-page":"S335","DOI":"10.1093\/infdis\/174.Supplement_3.S335","article-title":"Costs and benefits of routine varicella vaccination in German children (Structured abstract)","volume":"174","author":"Beutels","year":"1996","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2021.01.061_b0215","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1001\/jama.1994.03510290057037","article-title":"Cost-effectiveness of a routine varicella vaccination program for US children","volume":"271","author":"Lieu","year":"1994","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2021.01.061_b0220","article-title":"Risk of herpes zoster after exposure to varicella to explore the exogenous boosting hypothesis: self controlled case series study using UK electronic healthcare data","volume":"368","author":"Forbes","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2021.01.061_b0225","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1093\/cid\/ciy1099","article-title":"Systematic Review and Meta-analysis of Chickenpox Vaccination and Risk of Herpes Zoster: A Quantitative View on the \u201cExogenous Boosting Hypothesis\u201d","volume":"69","author":"Harder","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2021.01.061_b0230","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1080\/14760584.2019.1646129","article-title":"Do varicella vaccination programs change the epidemiology of herpes zoster? A comprehensive review, with focus on the United States","volume":"18","author":"Harpaz","year":"2019","journal-title":"Expert Review of Vaccines."},{"key":"10.1016\/j.vaccine.2021.01.061_b0235","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0025-5564(94)90070-1","article-title":"Epidemiologic effects of vaccines with complex direct effects in an age-structured population","volume":"121","author":"Halloran","year":"1994","journal-title":"Math Biosci"},{"key":"10.1016\/j.vaccine.2021.01.061_b0240","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/nature04153","article-title":"Superspreading and the effect of individual variation on disease emergence","volume":"438","author":"Lloyd-Smith","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2021.01.061_b0245","doi-asserted-by":"crossref","first-page":"S652","DOI":"10.1016\/j.jval.2019.09.1316","article-title":"What we know now: Revisiting the cost-effectiveness of chickenpox vaccination using an agent-based model","volume":"22","author":"Rafferty","year":"2019","journal-title":"Value Health"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21001006?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21001006?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:51:20Z","timestamp":1759402280000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X21001006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":49,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S0264410X21001006"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.01.061","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Modelling a cost-effective vaccination strategy for the prevention of varicella and herpes zoster infection: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.01.061","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}